Altium Capital Management LP Cti Biopharma Corp Transaction History

Altium Capital Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$4.2 - $6.01 $1.68 Million - $2.4 Million	400,000 Added 88.89%	850,000 $3.57 Million
Q4 2022 Feb 14, 2023	BUY	$4.45 - $6.17 $102,350 - $141,910	23,000 Added 5.39%	450,000 $2.7 Million
Q3 2022 Nov 14, 2022	BUY	$5.36 - $7.43 $2.29 Million - $3.17 Million	427,000 New	427,000 $2.49 Million
Q2 2022 Aug 15, 2022	SELL	$3.55 - $6.27 $1.06 Million - $1.88 Million	-299,800 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.9 - $5.23 $3.58 Million - $9.86 Million	-1,885,200 Reduced 86.28%	299,800 $1.4 Million
Q4 2021 Feb 14, 2022	SELL	$1.44 - $2.86 $1.62 Million - $3.23 Million	-1,128,000 Reduced 34.05%	2,185,000 $5.42 Million
Q3 2021 Nov 17, 2021	BUY	$2.25 - $3.18 $1.27 Million - $1.79 Million	563,656 Added 20.5%	3,313,000 $9.77 Million
Q3 2021 Nov 15, 2021	SELL	$2.25 - $3.18 $2.09 Million - $2.96 Million	-929,333 Reduced 25.26%	2,749,344 $7.62 Million
Q2 2021 Aug 13, 2021	BUY	$2.16 - $2.62 $6.67 Million - $8.09 Million	3,089,685 Added 524.57%	3,678,677 $9.2 Million
Q4 2020 Feb 16, 2021	BUY	$2.48 - $3.8 $1.46 Million - $2.24 Million	588,992 New	588,992 $1.9 Million

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Altium Capital Management LP with notifications on news.